Oak Family Advisors LLC Has $4.19 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Oak Family Advisors LLC lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 44.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 46,590 shares of the medical equipment provider’s stock after selling 37,733 shares during the quarter. Oak Family Advisors LLC’s holdings in Zimmer Biomet were worth $4,189,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of ZBH. Brighton Jones LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter worth $204,000. Sivia Capital Partners LLC acquired a new position in shares of Zimmer Biomet during the second quarter worth $232,000. United Bank lifted its holdings in shares of Zimmer Biomet by 10.7% during the second quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after purchasing an additional 1,153 shares during the period. Federated Hermes Inc. lifted its holdings in shares of Zimmer Biomet by 129.2% during the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock worth $194,000 after purchasing an additional 1,202 shares during the period. Finally, Cerity Partners LLC lifted its holdings in shares of Zimmer Biomet by 93.6% during the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock worth $7,004,000 after purchasing an additional 37,116 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president directly owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Price Performance

ZBH stock opened at $83.38 on Friday. The firm has a market cap of $16.13 billion, a price-to-earnings ratio of 21.66, a PEG ratio of 1.91 and a beta of 0.48. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.83 and a 12-month high of $108.29. The company’s fifty day simple moving average is $91.56 and its 200 day simple moving average is $92.31.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. During the same period in the previous year, the firm posted $1.81 earnings per share. The business’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.47 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend was Tuesday, March 31st. Zimmer Biomet’s payout ratio is 24.94%.

Analyst Ratings Changes

A number of brokerages have recently commented on ZBH. William Blair assumed coverage on shares of Zimmer Biomet in a report on Friday, February 20th. They set a “market perform” rating on the stock. Robert W. Baird set a $92.00 target price on shares of Zimmer Biomet in a report on Wednesday, April 29th. Leerink Partners assumed coverage on shares of Zimmer Biomet in a report on Monday, April 13th. They issued a “hold” rating and a $101.00 target price on the stock. Stifel Nicolaus dropped their target price on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. Finally, Citizens Jmp dropped their target price on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $102.80.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.